Metabolic syndrome: the danger signal in atherosclerosis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Atherosclerosis is a chronic inflammatory disease characterized by infiltration of blood vessels by lipids and leukocytes. There is a growing body of evidence that among risk factors that promote atherosclerosis, the metabolic syndrome is a powerful and prevalent predictor of cardiovascular events. The systemic inflammatory process associated with the metabolic syndrome has numerous deleterious effects that promote plaque activation, which is responsible for clinical events. Interactions between the innate immune system with lipid-derived products seem to play a major role in the pathophysiology of atherosclerosis in relation with the metabolic syndrome. The multiple links among adipose tissue, the vascular wall, and the immune system are the topics of this review, which examines the roles of oxidized low-density lipoprotein, inflammatory cytokines, and adipokines in triggering and perpetuating a danger signal response that promotes the development of atherosclerosis. Furthermore, therapeutic options that specifically target the metabolic syndrome components are reviewed in light of recent developments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Toll-like receptors in innate immunity
Takeda, K. (2004) · International Immunology · doi:10.1093/intimm/dxh186 · Cited by 3,328 · cited 1×
“Among the mammalian there are at least eleven TLRs that have been described, from which TLR1– 9 are conserved between human and mouse (Takeda and Akira 2005).”
BackgroundPPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
Yudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Van Snick, J. (1990) · Annual Review of Immunology · doi:10.1146/annurev.iy.08.040190.001345 · Cited by 1,890
A Randomized Trial of a Low-Carbohydrate Diet for Obesity
Foster, G. D., Wyatt, H. R., Hill, J. O., McGuckin, B. G., Brill, C., Mohammed, B. S., Szapary, P. O., Rader, D. J., Edman, J. S., & Klein, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022207 · Cited by 1,794 · cited 1×
“Whereas, weight loss at 6 months is increased in low-carbohydrate diet, there is no difference at one year with low-fat diet (Foster et al 2003; Stern et al 2004).”
BackgroundInflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?
Yudkin, J. S., Kumari, M., Humphries, S. E., & Mohamed-Ali, V. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00463-3 · Cited by 1,775
Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb
Jiang, J., & Struhl, G. (1998) · Nature · doi:10.1038/35154 · Cited by 1,735
High-Density Lipoprotein — The Clinical Implications of Recent Studies
Desforges, J. F., Gordon, D. J., & Rifkind, B. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211907 · Cited by 1,547
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
Self-citationStatins as a newly recognized type of immunomodulator.
Kwak, B., Mulhaupt, F., Myit, S., & Mach, F. (2000) · Nature Medicine · doi:10.1038/82219 · Cited by 1,383
A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis
Chawla, A., Boisvert, W. A., Lee, C.-H., Laffitte, B. A., Barak, Y., Joseph, S. B., Liao, D., Nagy, L., Edwards, P. A., Curtiss, L. K., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00164-2 · Cited by 1,347
Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325
Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity
Wang, Y.-X., Lee, C.-H., Tiep, S., Yu, R. T., Ham, J., Kang, H., & Evans, R. M. (2003) · Cell · doi:10.1016/s0092-8674(03)00269-1 · Cited by 1,296
Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., et al. (2001) · Nature Medicine · doi:10.1038/83348 · Cited by 1,170
Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069
Klein, S., Burke, L. E., Bray, G. A., Blair, S., Allison, D. B., Pi-Sunyer, X., Hong, Y., & Eckel, R. H. (2004) · Circulation · doi:10.1161/01.cir.0000145546.97738.1e · Cited by 934
Interleukin-6 induces cellular insulin resistance in hepatocytes.
Senn, J. J., Klover, P. J., Nowak, I. A., & Mooney, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3391 · Cited by 883 · cited 1×
“Indeed, it was recently demonstrated that IL-6 impaired insulin signaling in hepatocytes (Senn et al 2002).”
BackgroundTanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., Tachibana, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306981100 · Cited by 832
Stern, L., Iqbal, N., Seshadri, P., Chicano, K. L., Daily, D. A., McGrory, J., Williams, M., Gracely, E. J., & Samaha, F. F. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-10-200405180-00007 · Cited by 831 · cited 1×
“Whereas, weight loss at 6 months is increased in low-carbohydrate diet, there is no difference at one year with low-fat diet (Foster et al 2003; Stern et al 2004).”
BackgroundEffects of exercise and diet on chronic disease
Roberts, C. K., & Barnard, R. J. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00852.2004 · Cited by 556
Atherogenic Lipoprotein Particles in Atherosclerosis
Carmena, R., Duriez, P., & Fruchart, J.-C. (2004) · Circulation · doi:10.1161/01.cir.0000131511.50734.44 · Cited by 494 · cited 1×
“In light of the numerous pro-inflammatory activities of oxLDL, clinical studies have highlighted its role as a proatherogenic particle (Carmena et al 2004).”
BackgroundC-Reactive Protein: A Simple Test to Help Predict Risk of Heart Attack and Stroke
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000093381.57779.67 · Cited by 448 · cited 8×
“Obesity, particularly visceral adiposity, is associated with the clustering of metabolic perturbations, which is termed the metabolic syndrome, and is associated with a substantially increased CHD risk.”
BackgroundInfluentialCôté, M., Mauriège, P., Bergeron, J., Alméras, N., Tremblay, A., Lemieux, I., & Després, J.-P. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1711 · Cited by 230 · cited 1×
“Adiponectin blood levels are inversely correlated with visceral obesity, insulin resistance, and hyperlipidemia (Cote et al 2005).”
BackgroundLongevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine
Unger, R. H. (2005) · Biochimie · doi:10.1016/j.biochi.2004.11.014 · Cited by 184 · cited 1×
“It is thus believed that leptin-mediated actions are physiologically oriented in a response to decrease lipotoxicity in lean non-adipose tissue (Unger 2005).”
BackgroundWeber, C., Erl, W., & Weber, P. C. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1088 · Cited by 78 · cited 1×
“Ox-LDL recruits monocytes and T cells to the intima and promotes the transformation of monocytes into macrophages (Weber et al 1995).”
Background
Cited by
Scavenger receptors in homeostasis and immunity
Canton, J., Neculai, D., & Grinstein, S. (2013) · Nature Reviews Immunology · doi:10.1038/nri3515 · Cited by 838
Obesity, Inflammation, and Cardiovascular Risk
Mathieu, P., Lemieux, I., & Després, J.-P. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.311 · Cited by 419
Self-citationDevelopmental origins of health and disease: current knowledge and potential mechanisms
Hoffman, D. J., Reynolds, R. M., & Hardy, D. B. (2017) · Nutrition Reviews · doi:10.1093/nutrit/nux053 · Cited by 355
Basic Mechanisms of Calcific Aortic Valve Disease
Mathieu, P., & Boulanger, M.-C. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.03.029 · Cited by 107
Self-citationFisher, G., Hyatt, T. C., Hunter, G. R., Oster, R. A., Desmond, R. A., & Gower, B. A. (2011) · Obesity · doi:10.1038/oby.2010.310 · Cited by 103
“Current literature suggests that adipose tissue macrophage density increases with obesity, reducing production of anti-inflammatory adipokines, and increasing secretion of proinflammatory cytokines (24,25).”
Background
Metadata
- Authors
- Mathieu, P., Pibarot, P., & Despres, J.-P.
- Venue
- Vascular Health and Risk Management
- Publisher
- Informa UK Limited
- Published
- 2006-08
- Volume
- 2
- Issue
- 3
- Pages
- 285-302
- ISSN
- 1176-6344 (ISSN-L)
- OpenAlex
- W2063979477
- Cited by
- 114
- References
- 31
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.